Abstract: The application discloses a placement system for a door of a wafer pod, including a loadport. A docking interface is formed in the loadport, a placement mechanism is arranged on one side surface of the loadport, and includes a swing component, a follower component, and a docking plate. The swing component and the follower component are respectively connected to the docking plate, and the swing component can drive the docking plate to place the docking plate obliquely above the docking interface. By utilizing the space at the top of the loadport, the structural layout of the loadport is more reasonable; and the docking plate is placed nearly horizontally after the door is placed at a designated position, and provides a supporting force to the door, so that dependence on the vacuum suction is decreased, thereby avoiding the influences due to fluctuations of air pressure.

Abstract: The application discloses a placement system for a door of a wafer pod, including a loadport. A docking interface is formed in the loadport, a placement mechanism is arranged on one side surface of the loadport, and includes a swing component, a follower component, and a docking plate. The swing component and the follower component are respectively connected to the docking plate, and the swing component can drive the docking plate to place the docking plate obliquely above the docking interface. By utilizing the space at the top of the loadport, the structural layout of the loadport is more reasonable; and the docking plate is placed nearly horizontally after the door is placed at a designated position, and provides a supporting force to the door, so that dependence on the vacuum suction is decreased, thereby avoiding the influences due to fluctuations of air pressure.

Abstract: A method and an apparatus for signal synchronization are disclosed. The method for signal synchronization includes: A self-synchronizing first terminal device broadcasts first synchronization information, determines whether the first terminal device and a second terminal device have implemented signal synchronization when receiving second synchronization information sent by the second terminal device, and determines, based on a determining result, whether to synchronize with the second terminal device. This reduces a probability of communication interruption caused by synchronization source switching by the first terminal device after the second terminal device performs synchronization by using the first terminal device as a synchronization source. The method for signal synchronization may be applied to scenarios such as the intelligent driving, intelligent connected vehicles, and internet of vehicles.

Abstract: The present invention discloses a nitrogen-containing heterocyclic substituted benzoxazine oxazolidinone compound, a preparation method and use thereof in the manufacture of a medicament for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound represented by formula (I) and stereoisomer thereof, pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compounds of the present invention, use thereof, a method for preparing the compound, in which X1, X2, R1 and R2 are described in the specification.

Abstract: The present invention discloses a nitrogen-containing heterocyclic substituted benzoxazine oxazolidinone compound, a preparation method and use thereof in the manufacture of a medicament for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound represented by formula (I) and stereoisomer thereof, pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compounds of the present invention, use thereof, a method for preparing the compound, in which X1, X2, R1 and R2 are described in the specification.

Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Abstract: A method for producing a living tissue and organ includes: collecting medical image information of a target tissue and organ, and converting the medical image information into three-dimensional image information; performing machine recognition and multiple feature comparisons on the three-dimensional image information, and generating a primary three-dimensional model according to physiological structure data of tissues and organs in a tissue and organ database and a residual profile of the target tissue and organ; generating a complete three-dimensional model by producing an internal microstructure of the primary three-dimensional model with reference to the tissue and organ database; producing a full-scale physical model based on the complete three-dimensional model by an additive manufacturing process; and performing a living cell-based tissue reconstruction in the full-scale physical model to produce a living tissue and organ.

Abstract: A method for culturing osteocytes includes: obtaining an original three dimensional image of a bone tissue of a patient by collecting original image data of the bone tissue; determining a bone nidus and obtaining reverse data for fitting the bone nidus with normal bone parts other than the bone nidus by analyzing and dissecting the original three dimensional image; obtaining a preliminary three dimensional bone tissue image by simulating and matching the bone nidus and the normal bone parts other than the bone nidus based on the reverse data repeatedly; obtaining a complete three dimensional bone tissue image by designing an internal configuration of the preliminary three dimensional bone tissue image according to a bone tissue database; and obtaining a bone tissue culturing structure by printing the complete three dimensional bone tissue image through a multidimensional printer.

Abstract: A method for producing a living tissue and organ includes: collecting medical image information of a target tissue and organ, and converting the medical image information into three-dimensional image information; performing machine recognition and multiple feature comparisons on the three-dimensional image information, and generating a primary three-dimensional model according to physiological structure data of tissues and organs in a tissue and organ database and a residual profile of the target tissue and organ; generating a complete three-dimensional model by producing an internal microstructure of the primary three-dimensional model with reference to the tissue and organ database; producing a full-scale physical model based on the complete three-dimensional model by an additive manufacturing process; and performing a living cell-based tissue reconstruction in the full-scale physical model to produce a living tissue and organ.

Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Abstract: A method and a system for constructing prosthesis for defect part of tissues and organs are provided. The method includes the steps of obtaining a tissue defect site of a patient; collecting original image data of the tissue defect site of the patient, restoring an original three-dimensional image of the tissue defect site and a three-dimensional image of a defect part corresponding to the defect site, and generating and storing a three-dimensional model for mending the defect part; performing simulated mending on the basis of the three-dimensional model for mending the defect part and a tissue defect model; obtaining a three-dimensional model for mending the defect part, printing the three-dimensional model for mending the defect part and generating a physical model of the prosthesis.

Abstract: The present invention relates to compounds of Formula VIII with absolute configuration R or S: as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula VIII, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.

Abstract: The present invention discloses a control method, an apparatus, and a system. In the embodiments of the present invention, a control command is encapsulated into a network data packet to be sent to a remote network driver interface specification (RNDIS) device, and the encapsulated network data packet is sent to the RNDIS device to control the RNDIS device. In the conventional network architecture, a user device can directly send a network data packet to an RNDIS device. Therefore, with this solution, a control command can be transmitted to the RNDIS device without adding a new control interface. Compared with the solution that requires adding a new interface and installing an additional driver program in the prior art, this solution reduces application complexity and has no special requirement for the RNDIS device, which is commonly applicable and easy to implement.

Abstract: The present invention relates to compounds of Formula VIII with absolute configuration R or S: as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula VIII, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.

Abstract: The present invention relates to compounds of Formula I: as well as pharmaceutically acceptable salts, hydrates, isomers, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula I, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.

Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.

Abstract: Disclosed herein is a size-minimized data logger that also serves as a housing for a secure digital (SD) memory card. The SD card housing is located on one side of the data logger. The micro-SD card is used for recording raw or digital data and digitized event data. The data logger further includes, on the opposite side from the SD card housing, different functional units which are connected to one another. Exemplary functional units include an accelerometer, a magnetometer, a time unit, a temperature sensor and at least one analog/digital converter for conversion of measurement signals into digital input data, a processor unit for processing of data, a power supply source, an input interface for receiving signals or digital data and event data, and an output interface for outputting an indicator from the data logger.

Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.